insitro · 2 days ago
(Senior) Machine Learning Scientist, Oligonucleotides
South San Francisco, CA
Full-time
Hybrid
Mid, Senior Level
$185K/yr - $235K/yr
0+ years expinsitro is a drug discovery and development company using machine learning and data at scale to decode biology for transformative medicines. They are seeking a Senior Machine Learning Scientist to utilize their TherML platform in the design of oligonucleotide therapeutic programs while contributing to the development of ML models.
BiotechnologyHealth CareLife ScienceMachine LearningPharmaceuticalTherapeutics
Responsibilities
Develop insitro’s TherML Platform:
Work with industry-leading knockdown and off-target datasets to train and finetune foundation nucleotide models
Develop oligonucleotide generative AI methods for on-target knockdown and off-target gene misregulation
Collaborate with our computational chemists to apply MD simulation and other in-silico modeling based approaches to optimize oligonucleotide design based on RNA-protein interactions
Collaborate with software engineering teams to build robust pipelines for active/iterative learning and automated DMTL cycles
Directly shape the roadmap for our TherML platform's evolution
Integrate AI to Drive Our Oligonucleotide Discovery Programs:
Collaborate cross-functionally with machine learning scientists and oligonucleotide scientists to design and prioritize novel compounds using model outputs
Apply predictive models and AI-enabled design methods to solve real molecular optimization challenges across multiple therapeutic programs
Track performance of our on-target knockdown and off-target models on discovery programs and translate those insights into model improvements
Communicate model capabilities, results, limitations, and recommendations clearly to diverse stakeholders in regular discovery team meetings
Qualification
Required
PhD in computational biology, computer science, machine learning, cheminformatics, or related field
0-3+ years of industry experience applying machine learning to oligonucleotide therapeutic discovery
Strong programming skills in Python and modern deep learning frameworks (PyTorch or TensorFlow)
Demonstrated expertise in developing deep learning and/or generative AI methods for RNA and/or DNA
Understanding of RNA structure, siRNA/ASO mechanism of action, and mRNA design
Proficiency with genomic sequence analysis across species
Excellent communication skills with ability to translate technical concepts to diverse audiences
Familiarity with oligonucleotide therapeutics discovery process and design methods
Benefits
401(k) plan with employer matching for contributions
Excellent medical, dental, and vision coverage as well as mental health and well-being support
Open, flexible vacation policy
Paid parental leave of at least 16 weeks to support parents who give birth, and 10 weeks for a new parent (inclusive of birth, adoption, fostering, etc)
Quarterly budget for books and online courses for self-development
Support to attend professional conferences that are meaningful to your career growth and role's responsibilities
New hire stipend for home office setup
Monthly cell phone & internet stipend
Access to free onsite baristas and daily lunch for employees who are either onsite or hybrid
Access to a free commuter bus network that provides transport to and from our South San Francisco HQ from locations all around the Bay Area
Company
insitro
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
201-500 employees
H1B Sponsorship
insitro has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (12)
2023 (12)
2022 (7)
2021 (4)
2020 (8)
Funding
Current Stage
Growth StageTotal Funding
$643MKey Investors
CPP InvestmentsAndreessen Horowitz
2021-03-15Series C· $400M
2020-05-26Series B· $143M
2018-05-02Series A· $100M
Leadership Team
Daphne Koller
Founder and CEO
D
Divya Kanichar
Director
Recent News
2026-01-23
Company data provided by crunchbase